![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Monday, August 31, 2020 1:35:36 PM
MOSCOW (Reuters) - Comments by a senior U.S. official and moves by Britain towards the possible fast-tracking of COVID-19 vaccines show the West now accepts Russia was right to approve a vaccine as early as August, a Russian official said on Monday.
Russia granted regulatory approval to a COVID-19 vaccine this month after less than two months of human testing, prompting some Western experts to question its safety and efficacy.
The head of the U.S. Food and Drug Administration has since said he would be willing to bypass the normal approval process to authorize a COVID-19 vaccine as long as officials were convinced the benefits outweigh the risks.
The British government last week set out plans that would allow Britain's medical regulator to grant temporary authorization for any coronavirus vaccine before it has received a full license if it meets safety and quality standards.
The United States and London were now "exactly following the example of Russia," said Kirill Dmitriev, the head of the Russian Direct Investment Fund, Russia's sovereign wealth fund, which has been heavily involved in Russia's vaccine program.
"The Western world was shocked by Russia's success (in producing a potential vaccine) and had to go through four stages of accepting the inevitable: denial, anger, depression, and ultimately acceptance," he said in a statement.
"Recent statements show that we have already passed the stage of depression and it has now been accepted that Russia's approach is the correct one."
Russia has now begun Phase III trials of the "Sputnik V" vaccine that will test its efficacy on a bigger group of volunteers. It is also preparing to approve a second vaccine against COVID-19 in late September or early October.
Health Minister Mikhail Murashko has said mass vaccination of high-risk groups will begin in November-December.
(Editing by Andrew Osborn and Timothy Heritage)
Recent VXRT News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/20/2024 10:10:10 AM
- Vaxart Provides Business Update • GlobeNewswire Inc. • 06/17/2024 08:05:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 06/17/2024 10:02:10 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/14/2024 10:03:24 AM
- Vaxart Announces $40 Million Underwritten Offering of Common Stock • GlobeNewswire Inc. • 06/13/2024 11:07:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/13/2024 09:26:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/13/2024 08:36:53 PM
- Vaxart Receives BARDA-Funded Project NextGen Award Valued Up to $453 Million to Conduct a Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate • GlobeNewswire Inc. • 06/13/2024 08:15:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/13/2024 08:07:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/12/2024 08:40:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/12/2024 08:40:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/12/2024 08:39:43 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/12/2024 08:39:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/12/2024 08:38:42 PM
- Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 05/23/2024 08:01:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/13/2024 08:11:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2024 08:03:43 PM
- Vaxart Provides Business Update and Reports First Quarter 2024 Financial Results • GlobeNewswire Inc. • 05/13/2024 08:01:00 PM
- U.S. Futures Climb Amid High Expectations for Inflation Data; Global Markets Show Mixed Reactions • IH Market News • 05/13/2024 11:10:27 AM
- Vaxart to Host First Quarter 2024 Business Update and Financial Results Conference Call on May 13 • GlobeNewswire Inc. • 05/07/2024 12:00:00 PM
- Vaxart Announces Positive Results for Its Bivalent Norovirus Vaccine Candidate in Lactating Mothers • GlobeNewswire Inc. • 04/30/2024 12:00:39 PM
- Vaxart to Present at World Vaccine Congress Washington 2024 on April 3 • GlobeNewswire Inc. • 03/27/2024 12:00:00 PM
- Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 03/20/2024 12:00:13 PM
- Vaxart Provides Business Update and Reports Full Year 2023 Financial Results • GlobeNewswire Inc. • 03/14/2024 08:01:00 PM
- U.S. Stock Futures Rise Ahead Of PPI and Retail Sales; Oil Prices Climb • IH Market News • 03/14/2024 11:41:01 AM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM